ArticleTherapeutic advances in medical oncology2021

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.

Mark A Socinski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.